Therini Bio CEO Mike Quigley (L) and Katerina Akassoglou
April 27, 2023 06:00 AM EDT
Financing
Startups

Ex­clu­sive: Theri­ni rais­es $36M, will tar­get fib­rin pro­tein for Alzheimer's and di­a­bet­ic mac­u­lar ede­ma

Lei Lei Wu

News Reporter

Theri­ni Bio has raised a $36 mil­lion Se­ries A and will head to the clin­ic with an an­ti­body that neu­tral­izes fib­rin, a blood clot­ting pro­tein …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times